Clinical Trial

GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a randomized, double-blind, multicenter, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GM1 in preventing chemotherapy-induced peripheral neuropathy in breast cancer patients treated with Albumin-paclitaxel chemotherapy regimen.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-27.
Status change: Not Yet Recruiting → Recruiting 2025-08-05
Trial Details
NCT Number NCT06994507
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Chemotherapy-induced Peripheral Neuropathy (CIPN)
Enrollment 352 participants
Start Date 2025-08-01
Primary Completion 2026-09 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-08-06